Company intelligence / Profile preview
CoviCept Therapeutics
Rancho Santa Fe, California, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
CoviCept Therapeutics develops small-molecule antivirals targeting host proteins essential for the replication of RNA viruses. Their lead candidate has demonstrated efficacy against SARS-CoV‑2 and other RNA viruses in preclinical models and has shown good bioavailability and safety in humans. The company initiated a Phase 2 clinical trial with its oral antiviral PJS‑539 for COVID‑19 patients as of late 2021. The approach aims to provide a stockpiled therapeutic option with low risk of resistance due to its host-targeted mechanism.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Forbion Capital Partners (lead investor and operational support partner)
Beyond the preview
Go deeper on CoviCept Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CoviCept Therapeutics.